Tan et al. (2012) have shown that patients with CS have an increased lifetime risk (6%–85.2%) for cancers of the breast, thyroid, endometrium, colorectum, and kidney, as well as melanoma, and a robust, evidence‐based follow‐up strategy of patients with germline PTEN mutations has been proposed. This evidence concerns the gene PTEN and cancer.